Want to see VERA full AI Analyst Report?
VERA Stock Chart & Stats
$35.45
$0.05(0.14%)
At close: 4:00 PM EDT
$35.45
$0.05(0.14%)
Day’s Range― - ―
52-Week Range$19.07 - $56.05
Previous CloseN/A
Volume472.67K
Average Volume (3M)2.16M
Market Cap
$2.30B
Enterprise Value$2.35K
Total Cash (Recent Filing)$596.76M
Total Debt (Recent Filing)$75.03M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 06, 2026EPS Estimate
-1.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.54
Shares Outstanding71,782,906
10 Day Avg. Volume1,702,990
30 Day Avg. Volume2,159,832
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)5.38
Price to Sales (P/S)0.00
P/FCF Ratio-13.46
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$82.08Price Target Upside131.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-6.19
Revenue Forecast (FY)$29.55M
Bulls Say, Bears Say
Bulls Say
FDA Accelerated ApprovalAccelerated approval creates a structural shift from development-only to commercial-stage activities. It enables an initial revenue stream, commercialization planning, and payer engagement in a historically underserved nephrology segment, materially reducing regulatory risk for the lead program over the next 2-6 months.
Agreed Earlier EGFR AnalysisAn agreed, earlier eGFR analysis shortens the path to potential full approval and label expansion. This regulatory clarity accelerates decision points, reduces long-term uncertainty around confirmation endpoints, and can materially improve commercial planning and partner interest if results are positive.
Low Leverage And Sizable EquityA low debt burden and roughly $500M of equity provide financial flexibility to fund launch and late-stage activities without immediate solvency pressure. This balance sheet strength supports strategic optionality for partnering, staged commercialization, or paced financing over the coming months.
Bears Say
Pre-revenue With Widening LossesThe company remains pre-revenue while net losses have expanded materially, eroding reserves and shareholder equity. Without sustainable product sales, ongoing operating deficits heighten reliance on external capital and increase the risk of dilution or constrained investment in commercialization over the medium term.
Significant Rising Cash BurnOperating cash outflows are large and accelerating, with free cash flow consistently negative. This persistent burn drives near-term financing needs; if cash generation from TRUTAKNA launch lags, the company will face funding choices that could increase financing costs or shareholder dilution, constraining strategic flexibility.
Conditional Approval Reliant On ORIGIN 3 OutcomeAccelerated approval is contingent on confirmatory evidence; the ORIGIN 3 eGFR readout will determine full approval and broader label. A disappointing outcome would materially curtail market access and revenue potential, making near-term commercial upside dependent on a single upcoming trial result.
Vera Therapeutics News
VERA FAQ
What was Vera Therapeutics, Inc.’s price range in the past 12 months?
Vera Therapeutics, Inc. lowest stock price was $19.07 and its highest was $56.05 in the past 12 months.
What is Vera Therapeutics, Inc.’s market cap?
Vera Therapeutics, Inc.’s market cap is $2.30B.
When is Vera Therapeutics, Inc.’s upcoming earnings report date?
Vera Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Vera Therapeutics, Inc.’s earnings last quarter?
Vera Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.69 earnings per share for the quarter, missing the consensus estimate of -$1.328 by -$0.362.
Is Vera Therapeutics, Inc. overvalued?
According to Wall Street analysts Vera Therapeutics, Inc.’s price is currently Undervalued.
Does Vera Therapeutics, Inc. pay dividends?
Vera Therapeutics, Inc. does not currently pay dividends.
What is Vera Therapeutics, Inc.’s EPS estimate?
Vera Therapeutics, Inc.’s EPS estimate is -1.58.
How many shares outstanding does Vera Therapeutics, Inc. have?
Vera Therapeutics, Inc. has 71,782,906 shares outstanding.
What happened to Vera Therapeutics, Inc.’s price movement after its last earnings report?
Vera Therapeutics, Inc. reported an EPS of -$1.69 in its last earnings report, missing expectations of -$1.328. Following the earnings report the stock price went down -1.954%.
Which hedge fund is a major shareholder of Vera Therapeutics, Inc.?
Currently, no hedge funds are holding shares in VERA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vera Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$82.08 (131.53% Upside)
$82.08 (131.53% Upside)
Blogger Sentiment
Bullish
VERA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 342.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 17.3%
Last 30 Days ▲ 17.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.90%
Trailing 12-Months
Company Description
Vera Therapeutics, Inc.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
VERA Stock 12 Month Forecast
Average Price Target
$82.08
▲(131.53% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
8.94% Insiders
16.99% Mutual Funds
0.51% Other Institutional Investors
58.30% Public Companies and
Individual Investors